Acute Ischemic Stroke
Conditions
Brief summary
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
Detailed description
This is a multicenter, double-blind, randomized, and placebo-controlled prospective Phase II clinical study, designed to evaluate LT3001 drug product versus placebo in subjects with AIS. The study is planned to take place in multiple countries. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.
Interventions
Administered by intravenous infusion
DRUGPlacebo
Administered by intravenous infusion
Sponsors
Lumosa Therapeutics Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is aged 18 to 90 years. 2. Subject has an NIHSS of 6 to 25. 3. Subject is able to receive the first IP within 24 hours after stroke symptoms onset. Neuroimaging Inclusion Criteria: 1. Subject is able to undergo a contrast brain perfusion with either MRI or computed tomography (CT). 2. Subject has Target Mismatch Profile on MRI (perfusion is included) or CTP: ischemic core volume ≤70 mL, mismatch ratio ≥1.2 and mismatch volume ≥5 mL.
Exclusion criteria
1. Subject has been treated or intent to treat with endovascular thrombectomy and/or intravenous thrombolytic during the current AIS. 2. Subject has a pre-stroke disability (mRS ≥2). 3. Subject has large ischemic core volume \>70 mL or ASPECTS ≤5. 4. Subject has symptoms of suspected subarachnoid hemorrhage. 5. Subject has imaging evidence of acute intracranial hemorrhage, intracranial tumor, arteriovenous malformations, other central nervous system lesions that could increase the risk of bleeding, or aneurysm requiring treatment. 6. Subject has significant mass effect with midline shift. 7. Subject has pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations. 8. Subject has current uncontrolled hypertension despite treatment. 9. Subject has INR \>1.7 or abnormal aPTT or platelet count \<100,000/mm\^3. 10. Subject has received conventional heparin or new oral anticoagulants within 48 hours before the first IP administration. 11. Subject has blood glucose concentration \<50 mg/dL or \>400 mg/dL. 12. Subject has moderate or severe hepatic, renal, and/or active infectious disease. 13. Subject is lactating, pregnant, or planning to become pregnant during the study. 14. Subject has had history of sICH, prior AIS, myocardial infarction, or serious head trauma within 90 days before Screening. 15. Subject has had any major surgery within 90 days before Screening. 16. Subject has had a bleeding event within 21 days before Screening. 17. Subject has puncture of noncompressible vessels within 7 days before Screening. 18. Subject has participated in another investigational study and received IP within 30 days before Screening or 5 half-lives (whichever is longer). 19. In the opinion of the Investigator, the subject is not appropriate for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration. | within 90 days after the first IP administration | There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| LT3001 Drug Product Administered by intravenous infusion
LT3001 Drug Product: Administered by intravenous infusion | 43 |
| Placebo Administered by intravenous infusion
Placebo: Administered by intravenous infusion | 45 |
| Total | 88 |
Baseline characteristics
| Characteristic | Placebo | Total | LT3001 Drug Product |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 26 Participants | 50 Participants | 24 Participants |
| Age, Categorical Between 18 and 65 years | 19 Participants | 38 Participants | 19 Participants |
| Age, Continuous | 65.7 years STANDARD_DEVIATION 11.38 | 66.5 years STANDARD_DEVIATION 11.79 | 67.3 years STANDARD_DEVIATION 12.28 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 20 Participants | 42 Participants | 22 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) White | 23 Participants | 41 Participants | 18 Participants |
| Sex: Female, Male Female | 13 Participants | 27 Participants | 14 Participants |
| Sex: Female, Male Male | 32 Participants | 61 Participants | 29 Participants |
| Weight | 74.28 Kg STANDARD_DEVIATION 17.827 | 74.51 Kg STANDARD_DEVIATION 17.198 | 74.75 Kg STANDARD_DEVIATION 16.723 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 4 / 43 | 1 / 44 |
| other Total, other adverse events | 37 / 43 | 33 / 44 |
| serious Total, serious adverse events | 12 / 43 | 5 / 44 |
Outcome results
Primary
The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration.
There were no subjects in either treatment group who met the predefined criteria for the primary safety endpoint: the proportion of subjects with TEAEs judged to be probably or definitely related to the IP within 90 days after the first IP administration.
Time frame: within 90 days after the first IP administration
Population: Safety population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| LT3001 Drug Product | The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration. | 0 Participants |
| Placebo | The Proportion of Subjects With Adverse Events (AEs), Judged to be Probably or Definitely Related to the Investigational Product (IP), Within 90 Days After the First IP Administration. | 0 Participants |